Arca
Skip to content

Small cell lung cancer

Drug research and approvals for small cell lung cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 1,540 studies of small cell lung cancer are recruiting on ClinicalTrials.gov, Health Canada has authorized 383 drug trials for it since 2013, FDA has 48 approved and 71 open orphan designations naming it, and the EU has 30 authorised medicines for it.

  • Recruiting worldwide: 1,540
  • Trials authorized in Canada: 383
  • FDA orphan approvals: 48
  • EU medicines: 30

Recruiting Now

Newest start dates first, of 1,540 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

The 10 newest of 383; search them all in Canada trials
Nov 13, 2026A phase 3 randomized open-label study to evaluate the safety and efficacy of risvutatug rezetecan in combination with atezolizumab in participants with newly…RISVUTATUG REZETECAN (GSK5764227)GSKPending
Oct 27, 2026Luna-2: a phase II randomized trial of lnd101 for fecal microbiota transplantation in combination with immune checkpoint blockade and chemotherapy in…LND101CANADIAN CANCER TRIALS GROUP, CANCER RESEARCH INSTITUTE, QUEEN'S UNIVERSITYPending
Oct 22, 2026Rosetta lung-220: a phase 2, open-label, multicenter, multi-arm platform study evaluating pumitamig and other novel neoadjuvant regimens in participants with…PUMITAMIG (BMS-986545; BNT327)Bristol-Myers SquibbPending
Oct 15, 2026A phase 3 open label randomized study of telisotuzumab adizutecan compared to standard of care in subjects with previously treated, egfr wildtype, locally…TELISOTUZUMAB ADIZUTECAN (ABBV-400)AbbViePending
Oct 9, 2026A phase 3, open-label study of ivonescimab vs durvalumab as consolidation therapy in patients with locally advanced, unresectable nsclc (stage iii) who have…IVONESCIMABSUMMIT THERAPEUTICS INC.Pending
Sep 11, 2026A phase III, randomized, open-label study of izalontamab brengitecan (bms-986507) in combination with osimertinib versus osimertinib monotherapy or osimertinib…IZALONTAMAB BRENGITECAN (BMS-986507) / TAGRISSO (OSIMERTINIB)Bristol-Myers SquibbOngoing
Aug 27, 2026A phase III, randomised, double-blind, placebo-controlled, multicentre trial comparing efficacy and safety of trilaciclib versus placebo in participants with…TRILACICLIB / CISPLATIN / CARBOPLATIN / ETOPOSIDEPharmacosmosPending
Aug 19, 2026A phase 2, multicenter, open-label, single arm study of lurbinectedin in combination with durvalumab as first-line maintenance therapy in participants with…LURBINECTEDIN / DURVALUMABJazz PharmaceuticalsPending
Jun 30, 2026A global, multicentre, phase II platform study of datopotamab deruxtecan (dato-dxd)-based combinations in adult participants with trop2 nmr-positive non-small…DATOPOTAMAB DERUXTECAN / DURVALUMAB / CARBOPLATINAstraZeneca Pharmaceuticals LPPending
Jun 25, 2026An interventional, phase 1 b, double-blind, randomized, sponsor-open, 2-arm study to investigate the effect of ponsegromab on skeletal muscle mass and physical…PONSEGROMAB (PF-06946860)PfizerPending

FDA Orphan Designations

Approved first, then open designations, newest first; 15 of 119
Sep 9, 2026Hyrnuotreatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2…Bayer HealthCare Pharmaceuticals Inc.Approved
Jul 22, 2026Jideytrotreatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who received a prior ROS1…Nuvalent, Inc.Approved
Nov 19, 2025Hyrnuotreatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2…Bayer HealthCare Pharmaceuticals Inc.Approved
Oct 2, 2025Zepzelcain combination with atezolizumab or atezolizumab and hyaluronidase-tqjs, for the maintenance treatment of adult patients with…Jazz Pharmaceuticals Ireland LimitedApproved
Oct 2, 2025Tecentriqin combination with lurbinectedin, for the maintenance treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC)…Genentech, Inc.Approved
Jun 11, 2025Ibtrozitreatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC)Nuvation Bio Inc.Approved
Dec 4, 2024Imfinzias a single agent, for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed…AstraZeneca Pharmaceuticals LPApproved
Sep 25, 2024Tagrissotreatment of adult patients with locally advanced, unresectable (stage III) non-small cell lung cancer (NSCLC) whose disease has not…AstraZeneca Pharmaceuticals LPApproved
May 16, 2024Imdelltratreatment of adult patients with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based…Amgen Inc.Approved
Apr 18, 2024Alecensaadjuvant treatment in adult patients following tumor resection of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer…Hoffmann-La Roche, Inc. (c/o Genentech, Inc.)Approved
Feb 16, 2024Tagrissoin combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with locally advanced or…AstraZeneca Pharmaceuticals LPApproved
Nov 15, 2023Augtyrotreatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC)Bristol Myers Squibb CompanyApproved
Oct 11, 2023Braftoviin combination with binimetinib, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E…Array BioPharma Inc. (a wholly owned subsidiary of Pfizer Inc.)Approved
Sep 7, 2023Xalkoritreatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or…Pfizer, Inc.Approved
Dec 12, 2022KrazatiTreatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an…Bristol-Myers Squibb CompanyApproved

Medicines Authorised in the EU

Newest first; 15 of 30
May 29, 2026Imdylltratarlatamab · orphanAmgen Europe B.V.EMA ↗
May 29, 2026Zepzelcalurbinectedin · orphanPharma Mar S.A.EMA ↗
Feb 3, 2025HetroniflyserplulimabAccord Healthcare S.L.U.EMA ↗
Jan 20, 2025LazcluzelazertinibJanssen Cilag International NVEMA ↗
Jan 13, 2025AugtyrorepotrectinibBristol-Myers Squibb Pharma EEIGEMA ↗
Jul 24, 2024CejemlysugemalimabCstone Pharmaceuticals Ireland LimitedEMA ↗
Jan 5, 2024KrazatiadagrasibBristol-Myers Squibb Pharma EEIGEMA ↗
Sep 15, 2023TevimbratislelizumabBeone Medicines Ireland LimitedEMA ↗
Jun 20, 2022TabrectacapmatinibNovartis Europharm LimitedEMA ↗
Feb 16, 2022TepmetkotepotinibMerck Europe B.V.EMA ↗
Jan 6, 2022LumykrassotorasibAmgen Europe B.V.EMA ↗
Dec 9, 2021RybrevantamivantamabEMA ↗
Feb 11, 2021RetsevmoselpercatinibEli Lilly Nederland B.V.EMA ↗
May 6, 2019LorviqualorlatinibPfizer Europe MA EEIGEMA ↗
Apr 2, 2019VizimprodacomitinibPfizer Europe MA EEIGEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.